冠心病与肠道菌群失调的关系及靶向干预机制研究进展  

Relationship Between Coronary Heart Disease and Intestinal Flora Dysregulation and the Mechanism of Targeted Intervention

作　　者：涂诗琴 蒲鹏[1] 高凌云[1] TU Shiqin;PU Peng;GAO Lingyun(Department of Cardiovascular Medicine,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China)

机构地区：[1]重庆医科大学附属第一医院心血管内科,重庆400016

出　　处：《心血管病学进展》2024年第2期145-150,共6页Advances in Cardiovascular Diseases

基　　金：重庆市科卫联合医学科研项目(2019ZY3340)。

摘　　要：近年来,冠状动脉粥样硬化性心脏病(冠心病)的发病率逐年呈年轻化趋势,严重影响中国居民的生命健康。既往认为年龄、高血压、高脂血症等是冠心病发病的危险因素。近年来多项临床研究及动物模型研究证实肠道菌群失调、菌群中间代谢产物与冠心病的发生和发展存在密切关联,指出调控肠道菌群平衡可能是冠心病防治的新策略。现综述冠心病与肠道菌群失调的关系,并总结靶向肠道菌群及其代谢产物治疗冠心病的机制,以期指导冠心病的临床防治。In recent years,the morbidity of coronary atherosclerotic heart disease(CHD)has been trending towards youthfulness year by year,which seriously affects the life and health of Chinese residents.Previously,age,hypertension,hyperlipidaemia and other risk factors for the development of CHD were considered.In recent years,a number of clinical studies and animal model studies have confirmed that intestinal flora dysregulation,intermediate metabolites of flora and the occurrence and development of CHD have a close association,suggesting that regulating the balance of intestinal flora may be a new strategy for the prevention and treatment of CHD.This article reviews the relationship between CHD and intestinal flora dysregulation,and summarises the mechanism of targeting intestinal flora and its metabolites for the treatment of CHD,with a view to guiding the clinical prevention and treatment of CHD.

关 键 词：冠心病 肠道菌群失调 干预机制 

分 类 号：R541.4[医药卫生—心血管疾病]